Cargando…

Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study

Combination therapy with inhibitors of cytotoxic T lymphocyte-associated protein (CTLA)4 and programmed death (PD)-1 has demonstrated efficacy in cancer patients. However, there is little information on CTLA4 and PD-1 expression levels and their clinical significance across diverse cancers. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jian-Nan, Kong, Xiang-Shuo, Huang, Tao, Wang, Rui, Li, Wang, Chen, Qi-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539667/ https://www.ncbi.nlm.nih.gov/pubmed/33072070 http://dx.doi.org/10.3389/fimmu.2020.02048

Ejemplares similares

An integrated pan‐cancer analysis of TFAP4 aberrations and the potential clinical implications for cancer immunity
por: Liu, Jian‐Nan, et al.
Publicado: (2020)

Clinical Implications of Necroptosis Genes Expression for Cancer Immunity and Prognosis: A Pan-Cancer Analysis
por: Li, Xin-yu, et al.
Publicado: (2022)

Pan-cancer analysis of FBXW family with potential implications in prognosis and immune infiltration
por: Huang, Tingting, et al.
Publicado: (2022)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
por: Brunner-Weinzierl, Monika C., et al.
Publicado: (2018)

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
por: Cai, Zongqiang, et al.
Publicado: (2021)

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
por: Kong, Yi-chi M., et al.
Publicado: (2014)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis
por: Chen, Rui, et al.
Publicado: (2022)

Pan-cancer analysis of ASB3 and the potential clinical implications for immune microenvironment of glioblastoma multiforme
por: Mu, Long, et al.
Publicado: (2022)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model
por: Hu, Yun, et al.
Publicado: (2022)

Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1
por: Mathew, Divij, et al.
Publicado: (2021)

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
por: Zhang, Hao, et al.
Publicado: (2021)

Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment
por: Lv, Jingfang, et al.
Publicado: (2023)

The aberrant expression of rhythm genes affects the genome instability and regulates the cancer immunity in pan‐cancer
por: Zhou, Jian, et al.
Publicado: (2020)

PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis
por: Pereira, Joseph A., et al.
Publicado: (2023)

Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective
por: Khan, Muhammad, et al.
Publicado: (2022)

Clinical implications of aberrant PD-1 expression for acute leukemia prognosis
por: Ruan, Yanjie, et al.
Publicado: (2023)

Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker
por: Feng, Ziyang, et al.
Publicado: (2022)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4
por: Fisher, Katie, et al.
Publicado: (2023)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients
por: Vaddi, Prasanna Kumar, et al.
Publicado: (2023)

Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance
por: Rodriguez, B. Leticia, et al.
Publicado: (2023)

Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese
por: Huang, Xiaosheng, et al.
Publicado: (2021)

Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis
por: Tu, Zewei, et al.
Publicado: (2022)

Prognostic significances of PD-L1- and CTLA-4-positive T cells and positive correlations of immunosuppressive marker expression between cancer tissue and peripheral blood in patients with gastric cancer
por: Lee, Kun Hee, et al.
Publicado: (2023)

Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors
por: Qiao, Han, et al.
Publicado: (2022)

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy
por: Wang, Yusha, et al.
Publicado: (2022)

An integrative pan cancer analysis of RET aberrations and their potential clinical implications
por: Zhou, Lei, et al.
Publicado: (2022)

Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma
por: Zhu, Zheng-yi, et al.
Publicado: (2022)

MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis
por: Zhong, Chenming, et al.
Publicado: (2022)

The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response
por: Wu, Gujie, et al.
Publicado: (2022)

Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy
por: Chen, Yu, et al.
Publicado: (2022)

The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer
por: Sun, Xiaojiao, et al.
Publicado: (2022)

Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis
por: Zhao, Guang, et al.
Publicado: (2022)

Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response
por: Li, Zhanzhan, et al.
Publicado: (2023)

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023)

A signature for pan-cancer prognosis based on neutrophil extracellular traps
por: Zhang, Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_shoeadii76kgi52ga03s9e88ia